05:12 , May 29, 2018 |  BC Extra  |  Clinical News

Genmab slides as Darzalex combo trials discontinued

Genmab A/S (CSE:GEN; Pink:GMXAY) sank DKK239.30 (20%) to DKK953.20 in Copenhagen on Monday after it said partner Janssen Biotech Inc. will discontinue two studies of Darzalex daratumumab in combination with different immune checkpoint inhibitors. The studies...
18:09 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular atrophy Patient sample and mouse studies suggest inhibiting DKK3 could help treat sarcopenia. In vastus lateralis muscle samples from aged individuals with low body mass index (BMI), levels of DKK3 were higher than in...
08:00 , Nov 12, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Dickkopf homolog 3 (DKK3) and wingless-type MMTV integration site family member 1 (WNT1) to promote differentiation of induced pluripotent stem (iPS

DKK3WNT1Dickkopf homolog 3 (DKK3)wingless-type MMTV integration site family member 1 (WNT1)...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Lundbeck neurology news

Lundbeck will reduce headcount by about 1,000 (17%) to about 4,801 to cut costs and regain profitability. The restructuring is Lundbeck’s first major move since Kare Schultz took the helm as president and CEO in...
02:35 , Aug 20, 2015 |  BC Extra  |  Company News

Lundbeck restructuring

H. Lundbeck A/S (CSE:LUN) climbed DKK32.10 (19%) to DKK201 on Wednesday after unveiling restructuring plans designed to cut costs and regain profitability. The restructuring is Lundbeck's first major move since Kare Schultz took the helm...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) fell $4.44 (41%) to $6.39 on Monday after receiving a complete response letter from FDA for an NDA for Zalviso sufentanil sublingual tablet system to treat moderate-to-severe acute pain. AcelRx said...
22:35 , Jul 3, 2014 |  BC Extra  |  Company News

FDA approves Spectrum's belinostat

FDA granted accelerated approval to Beleodaq belinostat from Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). The approval came nearly a month ahead of the Aug. 9 PDUFA date. Spectrum...
23:50 , Jun 27, 2014 |  BC Extra  |  Clinical News

Lundbeck's desmoteplase misses in ischemic stroke

H. Lundbeck A/S (CSE:LUN) said IV desmoteplase given 3-9 hours from onset of stroke symptoms missed the primary endpoint vs. placebo in the Phase III DIAS-3 trial to treat acute ischemic stroke. Desmoteplase did not...
07:00 , May 12, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) slipped $2.25 to $152.87 last week after FDA granted full approval to Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS). The agency granted accelerated approval for Soliris for the...
07:00 , May 5, 2014 |  BC Week In Review  |  Financial News

Topotarget financial update

Topotarget said HealthCap decreased its stake in the company to 8.7% from 10%. Topotarget said said HealthCap's HealthCap III fund was established with a pre-determined "10-year life" and is now in its final stage of...